MUNDESINE® (forodesine hydrochloride) approved by Japan’s MHLW for relapsed or refractory Peripheral T-Cell Lymphoma

On 30th March 2017, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved MUNDESINE® (forodesine hydrochloride) for the treatment of Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL).

Mundipharma’s MUNDESINE® is an orally administered Purine Nucleoside Phosphorylase (PNP) inhibitor, and this approval is the first in the world for this type of agent. PNP inhibition results in increased levels of 2'-deoxyguanosine and buildup of intracellular deoxyguanosine 5'-triphosphate, initiating apoptosis.2

The compound is the first oral monotherapy for this indication and also holds Orphan Drug status in Japan. The approval is based on successful clinical trials.

  1. Mundipharma’s mundesine approved in Japan. 2017 Apr 03. [Accessed 2017 Apr 06].
  2. Furman R.R. & Hoelzer D. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Seminars in Oncology. 2007 Dec; 34(6 Suppl 5):S29–34.